Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Liabilities and Shareholders Equity (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Liabilities and Shareholders Equity for 2 consecutive years, with $6.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $6.7 million, compared with a TTM value of $25.4 million through Jun 2025, changed N/A, and an annual FY2024 reading of $5.8 million, changed N/A over the prior year.
  • Liabilities and Shareholders Equity was $6.7 million for Q2 2025 at Kairos Pharma, down from $7.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $7.9 million in Q1 2025 and bottomed at $5.0 million in Q3 2024.